Evidence map›Paper›PMID 41540036›Full record

ArticleCell death & disease2026

STK38-mediated feedback loop regulation of the hedgehog pathway governing tumor heterogeneity in renal papillary carcinoma.

Yifan Du, Xiuyuan Sui, Zeyuan Zheng, Zhengying Zhang, Bin Liu, Yang Bai, Yue Zhao, Qingqing Wu, Haodong Wu, Min Zhong and 3 more

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yifan Du *Department of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Xiuyuan Sui *Central Laboratory, School of Medicine, Xiamen University, Xiamen, China.
Zeyuan Zheng *Department of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Zhengying ZhangCentral Laboratory, School of Medicine, Xiamen University, Xiamen, China.
Bin LiuDepartment of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Yang BaiDepartment of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Yue ZhaoDepartment of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Qingqing WuDepartment of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Haodong WuDepartment of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Min ZhongDepartment of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.ORCID http://orcid.org/0009-0005-4526-4477
Liyan LiDepartment of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Huimin SunDepartment of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. hmsun@xah.xmu.edu.cn.
Chen ShaoDepartment of Urology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China. cshao@xah.xmu.edu.cn.ORCID http://orcid.org/0000-0002-6818-6660

Funding

Fujian Provincial Department of Science and Technology (Department of Science and Technology of Fujian Province) 2023D008Fujian Provincial Department of Science and Technology (Department of Science and Technology of Fujian Province) 2024J01014National Natural Science Foundation of China (National Science Foundation of China) 82472737National Natural Science Foundation of China (National Science Foundation of China) 82472738
6 · The paper itself

Abstract

Papillary renal cell carcinoma (pRCC) is characterized by marked intratumoral heterogeneity, which contributes to therapeutic resistance and disease progression. In this study, we identify STK38 as a key regulator of tumor heterogeneity in pRCC, functioning through non-canonical activation of the Hedgehog (Hh) signaling pathway. STK38 interacts with both KIF7 and GSK3β to promote Hh signaling by facilitating KIF7 ciliary localization and reprogramming GSK3β substrate selectivity, leading to GLI1 stabilization and β-catenin suppression. Moreover, GLI1 directly enhances STK38 transcription, establishing a positive feedback loop that reinforces pathway activation. Notably, depletion of STK38 sensitizes tumor cells to a NETosis-like chromatin release process (tNET release), a form of stress-induced nuclear expulsion associated with immune evasion and metastatic potential. Given the potential pro-metastatic consequences of STK38 inhibition, we instead targeted its downstream effector GLI1 using Glabrescione B, which potently suppressed tumor growth and induced apoptosis in both xenograft and patient-derived organoid models, particularly in STK38-high tumors. These findings position STK38 as a critical modulator of pRCC heterogeneity and support GLI1 inhibition as a promising strategy to disrupt oncogenic signaling while minimizing adverse effects.

Indexed as

Carcinoma, Renal CellHedgehog ProteinsKidney NeoplasmsProtein Serine-Threonine KinasesAnimalsCell Line, TumorFeedback, PhysiologicalGene Expression Regulation, NeoplasticGlycogen Synthase Kinase 3 betaHumansMiceSignal TransductionZinc Finger Protein GLI1Glycogen Synthase Kinase 3 betaHedgehog ProteinsProtein Serine-Threonine KinasesZinc Finger Protein GLI1

Identifiers

PMID41540036
PMCPMC12808802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.